Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) [EXTENSION OF 700242217]
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RANGE
- 04 Oct 2017 Last checked against ClinicalTrials.gov record
- 29 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 29 Oct 2015 Planned primary completion date changed to 1 Mar 2016 as reported by ClinicalTrials.gov.